### **Facilitating the Path for Regulation Harmonization**

#### African Society for Laboratory Medicine (ASLM) 2<sup>nd</sup> International Conference

Cape Town, December 3<sup>rd</sup>, 2014

Paul Tanui Senior Programme Officer-AMRH Programme

**AU-NEPAD Agency** 








# **NEPAD Agency Background**

- New Partnership for Africa's Development (NEPAD) Agency is a technical body of the African Union (AU)
- The mandate of the NEPAD Agency is to:
  - Facilitate and coordinate the implementation of continental and regional priority programmes and projects
  - Mobilize resources and partners in support of the implementation of Africa's priority programmes and projects
  - Conduct and coordinate research and knowledge management
  - Monitor and evaluate the implementation of programmes and projects; and,
  - Advocate on the AU and NEPAD vision, mission and core principles/values.
- NEPAD on-going projects in different sectors of the economy including in Health and in particular coordinating the African Medicines Regulatory Harmonization (AMRH) Programme and the PAHWP for Medical Devices and Diagnostics

### **NEPAD** vision of a harmonized future

	~ 54 regulatory regimes governing medical device regulation across Africa, at different levels of development and efficiency
Today	<ul> <li>Regulators capacity highly variable, some with almost no capacity at all</li> <li>Different requirements and formats, lack of clear guidelines</li> <li>Minimal transparency, No clear timelines</li> <li>Global regulatory efforts underleveraged</li> </ul>
Streamlined (harmonized) future	<ul> <li>Between 5-7 regional economic communities (RECs) covering the entire African continent</li> <li>Stronger, institutionalized regulatory capacity building programmes</li> <li>Clear guidelines, harmonized requirements, procedures and standards</li> <li>Transparent regulatory processes with clear timelines</li> </ul>
	Resource pooling and information sharing/mutual recognition of regulatory decisions

#### Long-term contribution of harmonization to public health and socio-economic development goals



#### **Rationale for harmonization** Why harmonization?

- **Duplication** in facility inspections and clinical trials results in increased costs, making products less affordable
- Approval processes in some countries are lengthy and not transparent, leads to costly delay in patient access
- Costly and lengthy regulatory approval are significant disincentive to innovation

#### Why now?

- **Substantial investment** in point-of-care diagnostics due to the recognition that inequity of access to diagnostics is a barrier to public health
- **Rapid technological advances** such as nanotechnology, microarrays is driving innovation
- Recognition that **regulatory barriers can stifle innovation**
- **Favourable environment** for harmonization, e.g. harmonization for registration of medicines in EAC, Asia Harmonization Working Party (AHWP), ALADDIV etc

### About Pan African Harmonization Working Party (PAHWP) on Medical Devices & Diagnostics

- PAHWP is a voluntary body that aims to improve access to safe and affordable medical devices and diagnostics in Africa though harmonized regulation
- Current priority is *in vitro diagnostic* devices
- PAHWP started through a series of consultative meetings with relevant stakeholders that began in Nairobi in July 2012; experiences and lessons learnt from other regions in the world was shared

## PAHWP..

- The PAHWP was conceived in 2012 following stakeholder meetings in East Africa, with an interim secretariat within the East African Community
- A base line survey of regulation of medical devices and medical diagnostics in EAC Partner States was undertaken in October 2012
- The formation of PAHWP was announced in a satellite symposium at the African Society for Laboratory Medicine Conference on 3rd December 2012 in Cape Town
- The EAC Regional Task Force on Regulation of Medical Devices and Diagnostics meeting held in April 2013 in Dar-es-Salaam approved the proposed structure which was presented at the 1st African Regulatory Forum on Medical Diagnostics in July 2013.


# PAHWP Vision, Mission & Goal

- The vision of PAHWP is that valuable, quality assured, safe medical devices and diagnostics are made available where needed
- The mission of the PAHWP is to protect public health
- Goal of PAHWP is to study and recommend ways to harmonize medical devices and diagnostics regulation in Africa

# **Expanding the reach of PAHWP**

- At the beginning participants included East African Community Health Secretariat (EAC) and the EAC partner States (Burundi, Rwanda, Kenya, Uganda, United Republic of Tanzania), Ethiopia, Nigeria and South Africa and the London School of Hygiene & Tropical Medicine. Partners include German International Co-operation (EAC-GIZ), the African Society for Laboratory Medicine (ASLM) and the World Health Organisation (WHO-AFRO, WHO-HQ). PAHWP has been anchored within the AU-NEPAD Agency regulatory harmonization programme
- Efforts underway to engage RECs e.g. SADC, ECOWAS/WAHO, member states (Ghana, Zimbabwe, Sierra Leone have recently participated) and industry associations

#### PAHWP is hosted within the African Union-NEPAD Planning and Coordinating Agency





### Five Priority Focus Areas for Regulatory Harmonization for PAHWP and their Impact

Regulation	Harmonization Priorities	Results	Impact
Risk Classification	A common risk classification system – adoption of the GHTF system	• More streamlined regulatory	• More affordable IVDs
Registration File	A common dossier template -Adoption of the WHO PQ dossier	<ul> <li>process</li> <li>Duplication in clinical performance studies and audits reduced</li> <li>Companies save time and money</li> </ul>	<ul> <li>Faster access to quality-assured diagnostics</li> </ul>
Clinical Performance Studies	Joint review of data from clinical performance studies		
Quality System Audits	Convergence of standards and 3rd party recognition of audits (MDSAP)		
Post- Marketing Surveillance	Regional laboratory networks to monitor test quality	<ul> <li>Assurance of diagnostic quality</li> </ul>	<ul> <li>More public confidence in diagnosis</li> </ul>

### **Regulatory Harmonization Activities**

**2012**:

Mar: East African Community (EAC) Medicines Harmonization meeting

Apr: Latin American Alliance for IVDs workshop

May: African Society for Laboratory Medicine POC Diagnostics Meeting

- July: EAC meeting to set up PAHWP
- **Oct: EAC-GIZ regulatory survey validation**
- Nov: Latin American Association for IVDs workshop
- **Dec:** AHWP 17<sup>th</sup> Annual meeting & **PAHWP launch at ASLM Conference**

#### **2013**:

May: AHWP IVD Working Group Workshop

- Apr: EAC Regional Task Force meeting
- July: 1st African Regulatory Forum for Medical Diagnostics
- Sep: Inter-regional workshop convened by AHWP
- **Oct: Latin American Association for IVDs**
- Nov: ISO TC 212: ISO standard for IVD clinical performance studies

Dec: AHWP 18<sup>th</sup> Annual meeting

**2014**:

Jan: 2<sup>nd</sup> African Regulatory Forum for Medical Diagnostics

Oct; Workshop with African manufacturers

Nov: AHWP 19th Annual Meeting

Nov: ALADDIV and PAHWP regulatory forum

### **Regulatory Harmonization Guidance for IVDs**

GHTF	AHWP WG01a	(AHWP-PAHWP-ALADDIV)
IVD Regulatory Framework	AHWG-GRM N1 F001 2013	IVD Regulatory Framework
GHTF MD/IVD Definitions	adopted (2014)	Additions not required
GHTF G1/N71		
Classification		Additions not required
GHTF SG1/N45		
Registration of manufacturers		Additions not required
/listing of devices GHTF SG1/N65		
Essential Principles	AHWP F002 2013	Additional guidance (2015)
GHTF SG1/N68, ISO 14971		
Common Registration File GHTF	STED/CSDT	Dossier – amalgamation of WHO
SG1/N63	(2014)	PQ, and STED/CSDT and ASEAN
Clinical evidence	Joint review of	Additional guidance:
GHTF SG5/N6,N7,N8	data <b>(2015-6)</b>	for: manufacturers (2015);
		For regulators <b>(2015</b> );
		ISO TC 212 Good Study Practice
Conformity Assessment	(2015)	Additional guidance (2016)
GHTF SG1/N46		
IVD Labelling GHTF SG1/N70	(2016)	Additional guidance (2016)
Quality Management System		ISO 13485 and Medical Device
Audits		Single Audit Program (MDSAP)
Post-marketing surveillance		Additional guidance
GHTF SG2/N8, N38		

# **Key PAHWP Meetings held**

With funding from a grant from Grand Challenges Canada to the LSHTM the following meeting were held:

- 1st African Regulatory Forum on Medical Diagnostics held July 2013 (Nairobi)
- Joint workshop with Asian Harmonization Working Party sub group on *in vitro* diagnostics held September 2013 (Taiwan)
- 2nd African Regulatory Forum on Medical Diagnostics held January 2014 (Cape Town)
- Workshop: policy framework and strategic plan for local production of in vitro diagnostics in developing countries October 2014
- 3<sup>rd</sup> African Regulatory Forum on Medical Diagnostics -November 2014 (Cape Town)
- Other training workshops; online learning materials; exercises









#### Recommendations of the 3<sup>rd</sup> African Regulatory Forum on Medical Diagnostics- ASLM Satellite: November 2014

• PAHWP confirmed its commitment to continue working within the framework of AU-NEPAD agency which has experience in African Medicines Harmonization program.

 PAHWP propose formation of a steering committee from heads of national regulatory authorities and national Laboratories to forge ahead PAHWP agenda and guide on the future of PAHWP. PAHWP therefore requests AU NEPAD to convene a meeting of Heads of Regulatory Authorities to effect the formation of steering committee.

• PAHWP recommends countries adopt a stepwise approach to harmonized regulation of medical devices and In Vitro Diagnostics and urge countries to identify 1-3 key priority areas for implementation in 2015.

### 3<sup>rd</sup> Regulatory Forum Recommendations..

- PAHWP requests AU-NEPAD to take up the role of monitoring implementation of PAHWP activities at the continental level.
- The PAHWP, coordinated by the AU NEPAD agency, welcomes the Diagnostic Access Initiative and will work in partner states, WHO, LSHTM, ASLM and any other partners to support harmonized regulatory guidance to ensure the quality of diagnostics.
- PAHWP under the coordination of AU NEPAD will establish a resource and learning centre to promote pooling and sharing of resources and capacity through e learning from a virtual campus.

# Training materials http://www.pahwp.org/5.html

Towards good review practice for clinical performance studies on *in vitro* diagnostics

Slide set 1: Workshop 1 on good practice in review of clinical performance data

Introduction to workshop

Slide set 2: Advanced workshop

Case study

Test your knowledge with a quiz

**On-line learning exercise** 



### **Joint Review of Clinical Performance Studies**

- Training Workshops on Joint Review of Data from Clinical Performance Studies
  - Basic workshop, Arusha, Tanzania, July 2014
  - Advanced workshop, Dar es Salaam, Tanzania, October
     2014
- Workshops will be held every 2-3 months in 2015
- E-learning materials available on PAHWP website

# 2015: **rolling program** of training in good review practice for clinical performance data

#### **Funded by UNITAID**



PAHWP - EAC - LSHTM TRAINING WORKSHOP ON ASSESSMENT OF CLINICAL PEFORMANCE OF IVDS 3<sup>rd</sup> - 4<sup>th</sup> JULY 2014 AT KIBO PALACE HOTEL ARUSHA - TANZANIA



#### NEPADVANCED TRAINING WORKSHOP 20-23rd OCTOBER 2014 DAR ES SALAAM



# **Risk Classification of IVDs: WHO 2014**




Table of Contents:

- 1. Introduction
- 2. Intended Audience and Scope
- 3. Definitions
- 4. Abbreviations
- 5. Risk Classification
- 6. Assessing IVDs Critical Elements
- 7. Performance Evaluations and Lot Release Testing
- 8. Conclusion
- 9. References

Annex 1. GHTF Classification Rules (refer to GHTF/SG1/N045:2008 "Principles of In Vitro Diagnostic (IVD) Medical Devices Classification")

### **Risk-based Approach to Regulation of IVDs**


An essential feature of a model authority includes "the construction of a regulatory system that is risk-based, i.e. a system that stratifies and applies premarket assessment controls based on the risk (or hazard) potential of a product, as well as the potential for misuse and the breadth of commercial distribution, known or projected."

CLASS	RISK LEVEL	EXAMPLES
Α	Low Individual Risk and Low Public Health Risk	Stains, culture reagents
В	Moderate Individual Risk and/or Low Public Health Risk	Home use pregancy tests, Urine test strips
С	High Individual Risk and/or Moderate Public Health Risk	Rapid tests for rubella, malaria
D	High Individual Risk and High Public Health Risk	Blood screening tests: HIV, HBV, HCV, HTLV

A Model Regulatory Program For Medical Devices: An International Guide. WHO, 2001.

<sup>1</sup> GHTF/SG1/N45:2008 Principles of In Vitro Diagnostic Medical Devices Classification

# **Common Registration File: Adopt** WHO's Dossier for Pre-qualification



#### Table of Contents:

- Introduction
- Product dossier elements
- The product dossier checklist
- The product
- Design and manufacturing information
- Product performance specifications and associated validation and verification studies
- Labelling
- Commercial history
- Regulatory history
- Quality Management System

### Post market surveillance

Sub-standard and IVD of unknown quality are sold in Africa

#### Challenges

- Lack of post market surveillance or batch testing of products
- Lack of platform for sharing information
- Lack of corrective and recall mechanisms

#### Response

- We shall establish an African communication portal and work towards a common information management system
- Pilot project on feasibility of active surveillance for rapid tests for HIV

# Conclusion

- PAHWP is evolving and need to tap into global efforts underway e.g. AHWP, ALADDIV, GHTF-IMDRF, WHO-PQ
- Realities of capacity limitations: lack of human technical capital and weak or absence of regulatory and legal frameworks for medical devices and diagnostics need to be addressed

# **Conclusion..**

 Several lessons have been learnt in Africa in the harmonization effort: process is slow, requires consultation; harmonization models exist; regulation based on science is key for harmonization; importance of effective legal and regulatory framework cannot be overemphasized; regulation to take into account issues of globalisation, crossborder trade, cross-border manufacturing should be considered in the harmonization agenda

# Acknowledgement

- PAHWP Executive & Technical Working Groups
- AU-NEPAD Agency
- London School of Hygiene & Tropical Medicine: Prof. Rosanna Peeling & Dr. Ruth McNerney
- EAC & EAC Partner States
- Participating Member States
- WHO (HQ & AFRO)
- ASLM
- EAC-GIZ
- Grand Challenges Canada
- AWHP, ALADDIV

### **THANK YOU**







# **OBRIGADO**